PREDICTOM

The PREDICTOM project includes hearing health as part of its initiative because recent research has found a significant link between hearing loss and the risk of developing dementia. GN is contributing to this project, focusing on the importance of understanding hearing loss as a risk factor and developing easily accessible solutions to identify individuals at earlier stages to support patients throughout their health journey toward maximum impact of available treatments. Early detection of Alzheimer’s is crucial, and PREDICTOM's AI screening platform aims to identify individuals at risk before symptoms manifest, which includes assessing various biomarkers, potentially including those related to hearing health.

‍

This project has received funding from the Innovative Health Initiative Joint Undertaking, under Grant Agreement no 101132356. This Joint Undertaking receives support from the European Union’s Horizon Europe research and innovation programme, COCIR, EFPIA, Europa Bio, MedTech Europe, Vaccines Europe, Novo Nordisk A/S, GN Hearing A/S, Pharmacoidea Hungary, GE HealthCare, Siemens Healthineers, Icometrix Nv Belgium, ALZpath Inc USA, Altoida Inc USA, BrainCheck Inc USA, and Muhdo Health Ltd.

‍

For a more detailed overview, you can read the full article here

‍